体外研究
Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppesses anchorage-dependent growth of HCT-116 and DLD1 cells in a dose- and time-dependent manner without cytotoxicity .
Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppresses CDK1 activity in a dose-dependent manner and inhibits CDK2 activity in HCT-116 cells.
Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) induces cell cycle arrest at the S and G2/M phases, the percentage of cells in S phase is higher in the 100 μM 6,7,4′-THIF-treated group, and the same pattern is observed in G2/M phase (29.5% versus 19.1% ) .
Cell Viability Assay
Cell Line:
HCT-116 cells
Concentration:
0, 12.5, 25, 50 or 100 μM
Incubation Time:
24, 48 or 72 hours
Result:
Inhibited anchorage-dependent and -independent growth of HCT-116 cells.
Western Blot Analysis
Cell Line:
HCT-116 and DLD1 cells
Concentration:
0, 25, 50 or 100 μM
Incubation Time:
48 hours
Result:
Inhibited CDK1,CDK2 expression.
Cell Cycle Analysis
Cell Line:
HCT-116 cells
Concentration:
0, 25, 50 or 100 μM
Incubation Time:
24, 48 or 72 hours
Result:
Induces cell cycle arrest of HCT-116 cells at S and G2/M phases.
体内研究
Desmethylglycitein (4',6,7-Trihydroxyisoflavone) (intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days) suppresses tumor development in mice and serves as an effective anticancer treatment with the potential to inhibit or delay the tumorigenicity of HCT-116 cells in an in vivo system.
Animal Model:
Female athymic nude mice subcutaneously injected with HCT-116 cells
Dosage:
5 or 25 mg/kg
Administration:
Intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days
Result:
Decreased tumor growth, volume and weight of HCT-116 xenografts.
